PANTHERx Rare Pharmacy, a specialty pharmacy focused on rare and orphan diseases, announced on Friday that it has ben selected by biopharmaceutical company Rhythm Pharmaceuticals Inc (Nasdaq:RYTM) as the exclusive US pharmacy distribution partner for the expanded indication of IMCIVREE (setmelanotide) for adults and children aged 4 years and older living with acquired hypothalamic obesity.

Acquired hypothalamic obesity is a rare disease characterised by accelerated and sustained weight gain caused by an injury to the hypothalamus. Acquired hypothalamic obesity most frequently follows the growth or treatment of craniopharyngioma, astrocytoma or other hypothalamic-pituitary tumours. Additional causes of injury may include traumatic brain injury, stroke or inflammation.

PANTHERx says that it will leverage its proprietary RxARECARE model to support patients, caregivers, and prescribers with therapy-specific clinical expertise.

PANTHERx has been the exclusive pharmacy distribution partner for IMCIVREE for chronic weight management in adult and paediatric patients 2 years of age and older with obesity due to Bardet-Biedl Syndrome and proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing since 2020.